Healthcare Industry News: Acute Kidney Injury
News Release - September 29, 2011
CorMedix Announces FDA Designation for Neutrolin (CRMD003)BRIDGEWATER, N.J.--(Healthcare Sales & Marketing Network)-- CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced that on September 15, 2011, the U.S. Food and Drug Administration (the “FDA”) advised CorMedix, that the Center for Drug Evaluation and Research (“CDER”) has been assigned as the lead agency for the pre-market review of Neutrolin®.
The Company will request a pre-Investigational New Drug (“pre-IND”) meeting with the FDA in preparation of filing an Investigational New Drug (“IND”) application. The FDA has 60 days to respond to the pre-IND meeting request. Once the Company submits an IND, the FDA has a statutory 30 days to review the IND submission. Once the FDA accepts the Company’s IND, the Company can begin clinical studies.
“We look forward to working with CDER’s anti-infective products group at the FDA in the development of Neutrolin,” stated, Mark A. Klausner, Chief Medical Officer.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including the outcome of clinical trials of CorMedix’s product candidates and whether they demonstrate these candidates’ safety and effectiveness; the risks and uncertainties associated with: obtaining additional financing to support CorMedix’s research and development and clinical activities and operations; obtaining regulatory approvals to conduct clinical trials and to commercialize CorMedix’s product candidates; CorMedix’s ability to enter into and maintain collaborations with third parties for its development programs; CorMedix’s dependence on its collaborations and its license relationships; achieving milestones under CorMedix’s collaborations; CorMedix’s’ dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers and consultants; protecting the intellectual property developed by or licensed to CorMedix; and CorMedix’s ability to maintain listing on NYSE Amex. These and other risks are described in greater detail in CorMedix’s filings with the Securities and Exchange Commission. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. CorMedix disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
CorMedix Inc. is a pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix’s goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications, in effect, treating the kidney to treat the heart. CorMedix currently has several product candidates in development, including its two most advanced product candidates: CRMD003 (Neutrolin®) for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients; and CRMD001 (a proprietary formulation of deferiprone) for the prevention of contrast induced Acute Kidney Injury in high-risk patients with chronic kidney disease. Please see www.cormedix.com for additional information.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.